Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - jentadueto
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mpdea6bb992c7a311f66506a0f31878b7e
identifier: http://ema.europa.eu/identifier
/EU/1/12/780/001 (10 x 1 film-coated tablets)
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Jentadueto 2.5 mg/850 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-dea6bb992c7a311f66506a0f31878b7e
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/12/780/001 (10 x 1 film-coated tablets)
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - jentadueto
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Metformin belongs to a class of medicines called biguanides. How Jentadueto works The two active substances work together to control blood sugar levels in adult patients with a form of diabetes called type 2 diabetes mellitus . Along with diet and exercise, this medicine helps to improve the levels and effects of insulin after a meal and lowers the amount of sugar made by your body. This medicine can be used alone or with certain other medicines for diabetes like sulphonylureas, empagliflozin, or insulin. What is type 2 diabetes? Type 2 diabetes is a condition in which your body does not make enough insulin, and the insulin that your body produces does not work as well as it should. Your body can also make too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.
alcohol-containing medicines. Jentadueto with alcohol Avoid excessive alcohol intake while taking Jentadueto since this may increase the risk of lactic acidosis (see section Warnings and precautions ). Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use Jentadueto if you are pregnant. It is unknown if this medicine is harmful to the unborn child. Metformin passes into human milk in small amounts. It is not known whether linagliptin passes into human milk. Talk to your doctor if you want to breast-feed while taking this medicine. Driving and using machines Jentadueto has no or negligible influence on the ability to drive and use machines. However, taking Jentadueto in combination with medicines called sulphonylureas or with insulin can cause too low blood sugar level (hypoglycaemia), which may affect your ability to drive and use machines or work without safe foothold.
with meals to lower your chance of an upset stomach. You should not exceed the maximum recommended daily dose of 5 mg linagliptin and 2,000 mg metformin hydrochloride. Continue to take Jentadueto as long as your doctor prescribes it so you can continue to help control your blood sugar. Your doctor may prescribe this medicine together with another oral anti-diabetic medicine or insulin. Remember to take all medicines as directed by your doctor to achieve the best results for your health. You should continue your diet during treatment with Jentadueto and take care that your carbohydrate intake is equally distributed over the day. If you are overweight, continue your energy-restricted diet as instructed. This medicine alone is unlikely to cause abnormally low blood sugar (hypoglycaemia). When Jentadueto is used with a sulphonylurea medicine or with insulin, low blood sugar can occur and your doctor may reduce the dose of your sulphonylurea or insulin. If you take more Jentadueto than you should If you take more Jentadueto tablets than you should have, you may experience lactic acidosis. Symptoms of lactic acidosis are non-specific such as feeling or being very sick, vomiting, stomach ache with muscle cramps, a general feeling of not being well with severe tiredness, and difficulty in breathing. Further symptoms are reduced body temperature and heartbeat. If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma. Stop taking this medicine immediately and contact a doctor or the nearest hospital straight away (see section 2). Take the medicine pack with you. If you forget to take Jentadueto If you forget to take a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. Never take two doses at the same time (morning or evening). If you stop taking Jentadueto Keep taking Jentadueto until your doctor tells you to stop. This is to help keep your blood sugar under control. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Very rare (may affect up to 1 in 10,000 people): hepatitis (a problem with your liver), skin reaction as redness of the skin (erythema). Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the blister, bottle and carton after EXP. The expiry date refers to the last day of that month. This medicine does not require any special temperature storage conditions. Blister: Store in the original package in order to protect from moisture. Bottle: Keep the bottle tightly closed in order to protect from moisture. Do not use this medicine if the package is damaged or shows signs of tampering. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Film coating: hypromellose, titanium dioxide (E171), talc, propylene glycol. Jentadueto 2.5 mg/850 mg film-coated tablets also contains iron oxide red (E172) and iron oxide yellow (E172). Jentadueto 2.5 mg/1,000 mg film-coated tablets also contains iron oxide red (E172). What Jentadueto looks like and contents of the pack Jentadueto 2.5 mg/850 mg are oval, biconvex, light orange, film-coated tablets (tablets). They have "D2/850" debossed on one side and the Boehringer Ingelheim logo debossed on the other. Jentadueto 2.5 mg/1,000 mg are oval, biconvex light pink film-coated tablets (tablets). They have "D2/1000" debossed on one side and the Boehringer Ingelheim logo debossed on the other. Jentadueto is available in perforated unit dose blisters with 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets and multipacks containing 120 x 1 (2 packs of 60 x 1), 180 x 1 (2 packs of 90 x 1), 180 x 1 (3 packs of 60 x 1) and 200 x 1 (2 packs of 100 x 1) film-coated tablets. Jentadueto is also available in plastic bottles with plastic screw cap and a silica gel desiccant. Bottles contain 14, 60 or 180 film-coated tablets. Not all pack sizes may be marketed in your country. Marketing Authorisation Holder Boehringer Ingelheim International GmbH Binger Strasse 55216 Ingelheim am Rhein Germany Manufacturer Boehringer Ingelheim Pharma GmbH & Co. KG Binger Strasse 55216 Ingelheim am Rhein Germany Boehringer Ingelheim Hellas Single Member S.A. 5th km Paiania Markopoulo Koropi Attiki, 19Greece Dragenopharm Apotheker P schl GmbH G llstra e 1 84529 Tittmoning Germany For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder: Belgi /Belgique/Belgien Boehringer Ingelheim SComm T l/Tel: +32 2 773 33 Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +370 5 2595 . -
: +359 2 958 79 Luxembourg/Luxemburg Boehringer Ingelheim SComm T l/Tel: +32 2 773 33 esk republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 Magyarorsz g Boehringer Ingelheim RCV GmbH & Co KG Magyarorsz gi Fi ktelepe Tel: +36 1 299 8Danmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 Malta Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9Deutschland Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 Nederland Boehringer Ingelheim b.v. Tel: +31 (0) 800 22 55 Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8Norge Boehringer Ingelheim Norway KS Tlf: +47 66 76 13
Boehringer Ingelheim . . T : +30 2 10 89 06 sterreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7Espa a Boehringer Ingelheim Espa a, S.A. Tel: +34 93 404 51 Polska Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 France Boehringer Ingelheim France S.A.S. T l: +33 3 26 50 45 Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 Rom nia Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucure ti Tel: +40 21 302 2Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podru nica Ljubljana Tel: +386 1 586 40 sland Vistor hf. S mi: +354 535 7Slovensk republika Boehringer Ingelheim RCV GmbH & Co KG organiza n zlo ka Tel: +421 2 5810 1Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102
Boehringer Ingelheim . . T : +30 2 10 89 06 Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas fili le Tel: +371 67 240 United Kingdom (Northern Ireland) Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9This leaflet was last revised in {MM/YYYY} Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-dea6bb992c7a311f66506a0f31878b7e
Resource Composition:
Generated Narrative: Composition composition-en-dea6bb992c7a311f66506a0f31878b7e
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/12/780/001 (10 x 1 film-coated tablets)status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - jentadueto
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mpdea6bb992c7a311f66506a0f31878b7e
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mpdea6bb992c7a311f66506a0f31878b7e
identifier:
http://ema.europa.eu/identifier
/EU/1/12/780/001 (10 x 1 film-coated tablets)type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Jentadueto 2.5 mg/850 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en